1. China Stocks

  2. •

    Process industries

  3. •

    Chemicals: agricultural
Huapont Life Sciences Co., Ltd. Class A

Huapont Life Sciences Co., Ltd. Class A

SSZSE:002004
4.21
CNY
+0.04
(+0.96%)
0.42EPS
12.41P/E
7.78BMarket Cap
Huapont Life Sciences Co., Ltd. Class A
SZSE:002004
(Shenzhen Stock Exchange)

Recent

price

4.21

P/E

ratio

12.41

div

yld

8.86%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.55
0.64
3.08
3.13
3.06
3.3
3.5
4.54
5.22
5.04
5.51
6.28
6.68
5.86
5.91
5.84
5.81
Revenue per Share
0.13
0.31
0.26
0.21
0.27
0.34
0.28
0.25
0.25
0.31
0.33
0.34
0.22
0.15
-0.15
0.36
0.32
Basic EPS, GAAP
0.02
0.04
-0.05
-0.02
-0.08
-0.26
-0.07
-0.19
0.4
0.32
0.58
0.01
0.64
0.15
0.34
0.74
- -
Free Cash Flow per Basic Share
0.01
0.01
0.15
0.19
0.26
0.28
0.36
0.38
0.49
0.48
0.48
0.43
0.43
0.38
0.38
0.34
0.37
Dividend per Share
0.99
1.9
2.14
2.63
3.26
4.68
4.74
4.7
4.48
4.72
4.86
5.1
5.15
5.1
4.72
5.16
5.1
Book Value per Share
0.86
1.03
1.07
1.6
1.93
2.63
2.57
2.19
2.02
2.23
2.28
2.49
2.77
2.89
2.87
3.35
3.3
Tangible Book Value per Share
990
991
1,259
1,428
1,590
1,872
2,025
2,023
2,026
2,001
1,975
1,980
1,980
1,980
1,975
1,973
1,973
Basic Weighted Avg Shares
541
638
3,877
4,465
4,867
6,174
7,093
9,183
10,574
10,091
10,876
12,431
13,232
11,595
11,665
11,512
11,460
Sales/Revenue/Turnover
20.01
16.65
10.29
10.21
11.61
13.51
11.83
10.09
13.49
15.74
14.33
13.02
15.18
12.96
10.9
13.09
13.25
Operating Margin (%)
37
39
106
133
210
320
331
417
587
607
696
748
800
891
969
1,061
- -
Depreciation Expense
132
305
332
303
429
637
567
506
506
620
652
668
433
302
-299
713
625
Net Income, GAAP
10.8
5.34
16.87
18.86
10.27
13.27
12.66
13.19
23.5
18.92
23.18
28.18
30.53
24.14
- -
16.7
21.62
Effective Tax Rate (%)
24.4
47.84
8.57
6.78
8.82
10.31
7.99
5.51
4.79
6.15
5.99
5.37
3.28
2.61
-2.56
6.19
5.45
Profit Margin (%)
128
387
-11
119
787
4,016
1,908
4,630
254
-901
-920
925
443
754
862
2,346
3,372
Working Capital
1
46
22
124
3,026
3,558
2,695
5,499
2,752
2,014
1,873
2,273
1,784
2,932
2,997
2,326
3,103
LT Debt
1,036
2,586
2,957
4,029
5,666
10,410
10,704
13,515
12,818
13,244
14,137
15,819
16,551
16,585
15,473
16,979
16,961
Total Equity
12.42
13.07
9.4
6.29
4.98
4.59
3.11
2.74
3.48
4.17
4.01
3.99
4.63
2.8
- -
3.58
3.34
Return on Invested Capital (%)
12.75
14.22
9.7
7.26
7.02
6.37
4.65
3.95
2.76
3.43
3.69
3.13
0.17
0.75
- -
3.3
2.53
Return on Capital (%)
14.56
18.13
13.1
9.32
9.21
8.47
5.91
5.26
5.42
6.72
6.87
6.77
4.27
2.98
-3.08
7.29
6.37
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,944
5,005
4,532
LT Borrowings
2,280
2,980
3,051
LT Finance Leases
47
51
52
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,980
1,980
1,980
Market Capitalization
9,464
10,355
7,781

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
11,460
12,393
11,950
Cash, Cash Equivalents & STI
3,852
4,899
4,398
Accounts Receivable, Net
2,124
2,235
2,320
Inventories
2,016
1,902
2,115
Total Current Liabilities
9,113
8,862
8,577
Payables & Accruals
- -
- -
- -
ST Debt
4,944
5,005
4,532
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.37%
3.95%
9.73%
Free Cash Flow
948.92%
1,928.41%
117.9%
Net Income, GAAP
-59.45%
-120.08%
-338.53%
Sales/Revenue/Turnover
7.04%
1.53%
-1.31%
Total Cash Common Dividend
3.8%
-6.51%
-11.38%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,915
3,007
2,988
2,755
11,665
2025
2,821
3,124
- -
2,426
11,512
2026
2,819
3,091
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.08
0.07
-0.38
-0.15
2025
0.09
0.1
- -
0.05
0.36
2026
0.08
0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.26
0.04
0.04
0.38
2025
0.03
0.03
- -
0.04
0.34
2026
0.03
0.28
- -
- -
- -
Similar Companies
UPL Limited (NSE:UPL)
Mosaic Company (The) (NYSE:MOS)
CF Industries Holdings, Inc. (NYSE:CF)
PhosAgro (MOEX:PHOR)
Abou Kir Fertilizers & Chemical Industries Co. (EGX:ABUK)
Misr Fertilizers Production Company MOPCO (EGX:MFPC)
Business
Huapont Life Sciences Co., Ltd. is a China-based biotechnology and pharmaceutical company specializing in the research, development, production, and sales of pharmaceutical preparations and intermediates. Its core product portfolio includes medicines for dermatology, tuberculosis, anti-infection, respiratory diseases, anti-tumor treatments, and ophthalmology, along with health management products. Additionally, the company provides pesticide technical products, intermediates, and preparations, as well as GLP registration technical services. It operates in the pharmaceutical, agrochemical, new materials, and tourism sectors, serving both domestic and international markets. Founded in 1992 and headquartered in Chongqing, China, Huapont has expanded its operations through strategic acquisitions, including a 2023 acquisition of a smaller biotech firm for approximately $50 million to enhance its product line and increase market capabilities. The company is focused on growing its healthcare business, which now represents its main strategic priority, supported by recent partnerships with research institutions targeting innovative drug development and regulatory compliance for international market expansion. Huapont continues to develop new pharmaceuticals for chronic diseases, has improved operational efficiencies, and participates actively in global pharmaceutical development events. Its former agrochemical subsidiary Beijing Nutrichem was listed independently, emphasizing Huapont's shift toward healthcare and biopharmaceutical growth. The company also engages in advancing nano-antibody drug research through joint ventures and invests heavily in research and development with a long-term commitment to expanding its healthcare product offerings and market presence.